Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 51.0%

Neg 51% Neu 0% Pos 0%

Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.